Search - tctmd.com

Displaying 1 - 13 of 13

Sort: Relevancy | Date

ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI

News Conference News ACC 2022

ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI

April 05, 2022

Subclinical Leaflet Thrombosis After TAVI Linked to Higher Mortality

News Daily News

Subclinical Leaflet Thrombosis After TAVI Linked to Higher Mortality

Michael O'Riordan

March 10, 2022

Apixaban Curbs Subclinical Thrombosis After TAVI in Patients Without Prior OAC

News Conference News ACC 2021

Apixaban Curbs Subclinical Thrombosis After TAVI in Patients Without Prior OAC

Michael O'Riordan

May 17, 2021

October 2020 News Roundup

News Opinion CV Team Dispatch

October 2020 News Roundup

October 01, 2020

Full GALILEO Results Confirm Harm With Rivaroxaban After TAVR

News Conference News AHA 2019

Full GALILEO Results Confirm Harm With Rivaroxaban After TAVR

November 17, 2019

AHA 2019: Beyond ISCHEMIA Are Plenty of Coronary, Structural, and HF Trials

News Conference News AHA 2019

AHA 2019: Beyond ISCHEMIA Are Plenty of Coronary, Structural, and HF Trials

November 11, 2019

Leaflet Thrombosis After TAVR Not Linked With Stroke, TIA, or Mortality Risk

News Daily News

Leaflet Thrombosis After TAVR Not Linked With Stroke, TIA, or Mortality Risk

Michael O'Riordan

June 20, 2018

Ticagrelor: Better Platelet Blockade Post-TAVR?

News Conference News CRT 2018

Ticagrelor: Better Platelet Blockade Post-TAVR?

Michael O'Riordan

March 07, 2018

Early Low-Risk TAVR Data Reassure, but Durability Questions Remain

News Conference News CRT 2018

Early Low-Risk TAVR Data Reassure, but Durability Questions Remain

Michael O'Riordan

March 05, 2018

Clinical Leaflet Thrombosis After TAVR Tied to Cardiogenic Shock and Death

News Conference News ESC 2017

Leaflet Thrombosis After TAVR Tied to Cardiogenic Shock and Death

Yael L. Maxwell

September 01, 2017

Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery

News Conference News ACC 2017

Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery

Michael O'Riordan

March 19, 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

March 10, 2017

News Daily News

Best Anticoagulant in the TAVR Patient With A-fib? Small Study Makes Case for Apixaban

Michael O'Riordan

January 03, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.